Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | HTR1D | P28221 | 3/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163398 | 0.84 | HTR2A (0.66) | HTR2AHTR1DTRPM8HTR1AHTR2C | |
| SCHEMBL1163155 | 0.82 | HTR2A (0.67) | HTR2AHTR1DTRPM8HTR1AHTR2C | |
| SCHEMBL13592867 | 0.81 | HTR1A (0.50) | HTR2AHTR1DTRPM8HTR1AHTR2C | |
| SCHEMBL4397110 | 0.78 | HTR2A (0.42) | HTR2AHTR1DTRPM8HTR2CHTR2B | |
| SCHEMBL1163811 | 0.76 | HTR2A (0.71) | HTR2AHTR1DTRPM8HTR1AHTR2C | |
| SCHEMBL30954332 | 0.76 | HTR2A (0.71) | HTR2AHTR1DTRPM8HTR1AHTR2C | |
| SCHEMBL24420538 | 0.76 | HTR1A (0.69) | HTR2AHTR1DHTR1AHTR2CHTR2B | |
| SCHEMBL27189518 | 0.75 | HTR2A (0.67) | HTR2AHTR1DTRPM8HTR1AHTR2C | |
| SCHEMBL27189554 | 0.75 | HTR2A (0.64) | HTR2AHTR1DTRPM8HTR1AHTR2C | |
| SCHEMBL27189559 | 0.74 | HTR2A (0.66) | HTR2AHTR1DTRPM8HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | HTR2A 27/4885HTR1D 50/4885TRPM8 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.